CVS Group plc (CVSG), one of the UK's leading veterinary services operators, has announced the purchase of 100,000 of its own ordinary shares between 2 and 6 November 2026, executed through Joh. Berenberg, Gossler & Co. KG, London Branch. The shares were acquired at prices ranging from 1,321p to 1,412p each, with a volume weighted average price of 1,364.58p. All purchased shares are to be cancelled, reducing the company's total shares in issue to 66,595,634. Investors tracking CVS's capital return activity may note that the buyback programme has now repurchased over 3.5 million shares since it commenced in May 2026.

Key Points

  • CVS Group plc (CVSG), listed on the Main Market of the London Stock Exchange
  • 100,000 ordinary shares of 0.2 pence each purchased between 2 and 6 November 2026 and to be cancelled
  • Volume weighted average price of 1,364.58p per share; programme-to-date weighted average price of 1,254.0p across 3,567,465 shares repurchased in aggregate
  • Investors should watch the pace of remaining buyback capacity and any further regulatory notifications as the total voting rights figure adjusts to 66,595,634

CVS Group Repurchases 100,000 Ordinary Shares Between 2 and 6 November 2026

CVS Group executed the latest tranche of its share buyback programme through Berenberg, purchasing 100,000 ordinary shares across the five trading days ending 6 November 2026. The lowest price paid during the period was 1,321.00p per share, while the highest reached 1,412.00p, producing a volume weighted average price of 1,364.58p. The company states that all shares acquired under this transaction will be cancelled rather than held in treasury, directly reducing the number of shares in circulation and consequently the total voting rights attributable to CVS ordinary shareholders.

Share Buyback Programme Totals 3,567,465 Shares Since May 2026 Launch

Since the Share Buyback Programme was first announced on 26 May 2026, CVS Group has repurchased 3,567,465 ordinary shares in aggregate, at a weighted average price of 1,254.0 pence per share across all completed tranches. This latest weekly purchase was executed at a notably higher average than the programme-wide figure, reflecting price movements over the intervening period. The buyback is conducted in compliance with Article 5(1)(b) of Regulation (EU) No 596/2014, as retained in UK law under the European Union (Withdrawal) Act 2018, with full individual trade data published via the London Stock Exchange's RNS service.

Post-Cancellation Voting Rights Stand at 66,595,634 for CVS Shareholders

Following settlement and cancellation of the 100,000 shares, CVS Group confirms its total shares in issue will be 66,595,634, with no shares held in treasury. This figure represents the denominator shareholders must use when calculating whether they are required to disclose interests or changes in interests under the Financial Conduct Authority's Disclosure and Transparency Rules. CVS operates over 475 veterinary practices across the UK and Australia, employing 9,000 personnel including 2,500 veterinary surgeons, and also runs diagnostic laboratories and the Animed Direct online retail business.